|
|
Post by agedhippie on May 30, 2016 8:31:55 GMT -5
At this point the JV in the form of Sanofi effectively still set the price as they are the only ones selling so unless Mannkind drops the price to Sanofi I cannot see the price moving. Sanofi is still taking a loss on each unit of Afrezza they sell and are not going to be keen on taking a bigger loss! I wouldn't think any loss now as it's just the product cost and distribution cut. No other costs Vice President's , US lead , director 's shouldn't be charging to the JAC. But not so sure what else being charged as mnkd had 5 mil l?? oss from JAC in the first Q Good point. We can drop out the whole sales and marketing element. That just leaves the cost of goods and operations. With the level of sales what they are I think they are still probably making a loss. Ultimately at this point Sanofi control the price and I cannot see why they would want to drop it. |
|
|
|
Post by agedhippie on May 30, 2016 8:48:23 GMT -5
At this point the JV in the form of Sanofi effectively still set the price as they are the only ones selling so unless Mannkind drops the price to Sanofi I cannot see the price moving. Sanofi is still taking a loss on each unit of Afrezza they sell and are not going to be keen on taking a bigger loss! Has MNKD inquired of SNY about lowering the price? What is the shelf life? Reading through some tweets left an impression that at least some SNY material is expiring in September, I would think perhaps SNY might be willing to lower the price to help move inventory out before it expires. I don't know what Mannkind have done. They may have asked but Sanofi would probably want to drop their purchase price to compensate and I cannot see Mannkind wanting to do that at this time. With the level of sales I don't think the expiry numbers are going to be significant enough for Sanofi to want to disrupt their distribution chain - they need the distributors for their other drugs. On top of that 35% of the loss goes to Mannkind (although at a substantial risk to Sanofi). |
|
|
|
Post by capnbob on May 30, 2016 11:55:45 GMT -5
Has MNKD inquired of SNY about lowering the price? What is the shelf life? Reading through some tweets left an impression that at least some SNY material is expiring in September, I would think perhaps SNY might be willing to lower the price to help move inventory out before it expires. I don't know what Mannkind have done. They may have asked but Sanofi would probably want to drop their purchase price to compensate and I cannot see Mannkind wanting to do that at this time. With the level of sales I don't think the expiry numbers are going to be significant enough for Sanofi to want to disrupt their distribution chain - they need the distributors for their other drugs. On top of that 35% of the loss goes to Mannkind (although at a substantial risk to Sanofi). The woman -- "Laura" something -- tweeted that the pharmacy had some but that it would expire in September and they were still trying to locate some that would expire later. She did eventually say they found more that would expire in December. The thing is, if MNKD was expecting big sales, then one might suspect that they had the lines running full time and that a significant amount from those early runs could be bumping into expiration pretty soon. MNKD might suggest to SNY to start giving it away as free sample packs. Better than having to dump it. |
|
|
|
Post by nylefty on May 30, 2016 14:20:46 GMT -5
I don't know what Mannkind have done. They may have asked but Sanofi would probably want to drop their purchase price to compensate and I cannot see Mannkind wanting to do that at this time. With the level of sales I don't think the expiry numbers are going to be significant enough for Sanofi to want to disrupt their distribution chain - they need the distributors for their other drugs. On top of that 35% of the loss goes to Mannkind (although at a substantial risk to Sanofi). The woman -- "Laura" something -- tweeted that the pharmacy had some but that it would expire in September and they were still trying to locate some that would expire later. She did eventually say they found more that would expire in December. The thing is, if MNKD was expecting big sales, then one might suspect that they had the lines running full time and that a significant amount from those early runs could be bumping into expiration pretty soon. MNKD might suggest to SNY to start giving it away as free sample packs. Better than having to dump it. Why would Sanofi do that? Remember, they want Afrezza to fail. |
|
|
|
Post by rravis1914 on May 30, 2016 17:25:56 GMT -5
Moderator:
Is there a list of recent threads/posts? Where can I find such a list?
|
|
|
|
Post by anderson on May 30, 2016 18:23:13 GMT -5
I don't know what Mannkind have done. They may have asked but Sanofi would probably want to drop their purchase price to compensate and I cannot see Mannkind wanting to do that at this time. With the level of sales I don't think the expiry numbers are going to be significant enough for Sanofi to want to disrupt their distribution chain - they need the distributors for their other drugs. On top of that 35% of the loss goes to Mannkind (although at a substantial risk to Sanofi). The woman -- "Laura" something -- tweeted that the pharmacy had some but that it would expire in September and they were still trying to locate some that would expire later. She did eventually say they found more that would expire in December. The thing is, if MNKD was expecting big sales, then one might suspect that they had the lines running full time and that a significant amount from those early runs could be bumping into expiration pretty soon. MNKD might suggest to SNY to start giving it away as free sample packs. Better than having to dump it. Hmm actually it might be good to get a some of that insulin back. Maybe they could do a shelf life study and we could see how stable Afrezza really is. Companies and the FDA are really just guessing when it comes to shelf life. Take a look at the article below: www.medicaldaily.com/what-your-pharmacist-cant-tell-you-about-drug-expiration-dates-its-complicated-342978 |
|
|
|
Post by mnkdfann on May 30, 2016 22:45:08 GMT -5
The woman -- "Laura" something -- tweeted that the pharmacy had some but that it would expire in September and they were still trying to locate some that would expire later. She did eventually say they found more that would expire in December. The thing is, if MNKD was expecting big sales, then one might suspect that they had the lines running full time and that a significant amount from those early runs could be bumping into expiration pretty soon. MNKD might suggest to SNY to start giving it away as free sample packs. Better than having to dump it. Hmm actually it might be good to get a some of that insulin back. Maybe they could do a shelf life study and we could see how stable Afrezza really is. Companies and the FDA are really just guessing when it comes to shelf life. Such a study might help in future years, but I do not see how it could be applied to existing supplies. |
|
|
|
Post by anderson on May 31, 2016 5:10:47 GMT -5
Hmm actually it might be good to get a some of that insulin back. Maybe they could do a shelf life study and we could see how stable Afrezza really is. Companies and the FDA are really just guessing when it comes to shelf life. Such a study might help in future years, but I do not see how it could be applied to existing supplies. Take the return from Sanofi and stick it in a warehouse and test some every now and then. Didnt say it would help out now, but why throw the stuff away when you can put it to a purpose. |
|
